Do The Benefits Outweigh The Risks?FDA Advisor Paul Offit Was Not Happy With The Latest "Booster" DecisionMathew AldredJul 18, 2022∙ Paid10ShareThis post is for paid subscribersAlready a paid subscriber? Sign in